MedTrace Logo

A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

NCT04083716 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-11-29

No results posted yet for this study

Summary

This study is designed to assess the relative bioavailability of ABI-H2158 tablets (Test Formulation) compared to ABI-H2158 tablets (Reference Formulation). The effect of food on the pharmacokinetics of the Test Formulation will also be evaluated under fed and fasting conditions.

Conditions

Interventions

DRUG

ABI-H2158 Reference Formulation

ABI-H2158 tablets Reference Formulation

DRUG

ABI-H2158 Test Formulation

ABI-H2158 tablets Test Formulation

Sponsors & Collaborators

  • Assembly Biosciences

    lead INDUSTRY

Principal Investigators

  • Marc Evanchik · Assembly Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-06
Primary Completion
2019-10-05
Completion
2019-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04083716 on ClinicalTrials.gov